Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTHONY PHAM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1790913994
CMS profile
414361
Location
TIGARD, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$313.91

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $303.10 2
Education $10.81 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Sirtex Medical Inc $188.93 1
Biocompatibles, Inc. $114.17 1
Merck Sharp & Dohme Corporation $10.81 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTHONY PHAM

NPI 1790913994 · CMS profile ID 414361

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TIGARD, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790913994?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTHONY PHAM, NPI 1790913994, CMS profile ID 414361. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790913994?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ANTHONY PHAM, NPI 1790913994, CMS profile ID 414361. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790913994?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ANTHONY PHAM, NPI 1790913994, CMS profile ID 414361, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790913994?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $313.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biocompatibles, Inc. $114.1705/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694928611 CMS
Merck Sharp & Dohme Corporation $10.8104/30/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695441927 CMS
Sirtex Medical Inc $188.9304/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704667547 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $313.91 3
PY2021 $11.92 1
PY2022 $20.37 1
PY2024 $1,526.50 3
PY2025 $42.02 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $137,823.93 11
PY2024 Principal investigator $177,934.43 55
PY2023 Principal investigator $55,995.30 21
PY2022 Principal investigator $107,416.20 14
PY2021 Principal investigator $90,559.20 10
PY2020 Principal investigator $68,353.40 8
PY2019 Principal investigator $122,830.54 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Mirati Therapeutics, Inc. $956.00 10/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1058028425
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 09/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1058026731
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 09/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1058026737
Principal investigator 1 Mirati Therapeutics, Inc. $956.00 07/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1058023501
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 07/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1058023613
Principal investigator 1 Genentech, Inc. $6,921.00 07/10/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040572986
Principal investigator 1 Genentech, Inc. $1,363.60 07/05/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040572823
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 05/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1058012593
Principal investigator 1 Mirati Therapeutics, Inc. $956.00 04/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1058007713
Principal investigator 1 Genentech, Inc. $11,680.00 04/12/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040573551
Principal investigator 1 Genentech, Inc. $1,250.00 04/12/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040573633
Principal investigator 1 Aveo Pharmaceuticals, Inc. $7,000.00 03/20/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049073909
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 03/15/2023 Non-covered Recipient Entity
KETTERING MEMORIAL HOSPITAL
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1058003815
Principal investigator 1 Genentech, Inc. $3,819.60 03/01/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040573415
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,123.10 01/15/2023 Non-covered Recipient Entity
COMPASS ONCOLOGY EAST
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991128117
Principal investigator 1 Eli Lilly and Company $4,250.00 01/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER No dispute reported 06/30/2026 1038118067
Principal investigator 1 Mirati Therapeutics, Inc. $956.00 01/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1057991037
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 01/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1057991589
Principal investigator 1 Mirati Therapeutics, Inc. $310.00 01/15/2023 Non-covered Recipient Entity
NORTHWEST CANCER SPECIALISTS PC
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE No dispute reported 06/30/2026 1057991601
Principal investigator 1 Genentech, Inc. $9,344.00 01/06/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040573345
Principal investigator 1 Genentech, Inc. $1,250.00 01/03/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tecentriq Oncology Extension Study No dispute reported 06/30/2026 1040573715